KRAS mutations are prevalent in several types of cancer, including pancreatic cancer (approximately 90%), colorectal cancer (about 40%), and non-small cell lung cancer (NSCLC) (around 25%). These mutations are often associated with poor prognosis and resistance to certain therapies.
